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Abstract
Purpose This study was designed to compare baseline
data and clinical outcome between patients with prostate
enlargement/benign prostatic hyperplasia (PE/BPH) who
underwent unilateral and bilateral prostatic arterial embo-
lization (PAE) for the relief of lower urinary tract symp-
toms (LUTS).
Methods This single-center, ambispective cohort study
compared 122 consecutive patients (mean age 66.7 years)
with unilateral versus bilateral PAE from March 2009 to
December 2011. Selective PAE was performed with 100-
and 200-lm nonspherical polyvinyl alcohol (PVA) parti-
cles by a unilateral femoral approach.
Results Bilateral PAE was performed in 103 (84.4 %)
patients (group A). The remaining 19 (15.6 %) patients
underwent unilateral PAE (group B). Mean follow-up time
was 6.7 months in group A and 7.3 months in group B. Mean
prostate volume, PSA, International prostate symptom score/
quality of life (IPSS/QoL) and post-void residual volume
(PVR) reduction, and peak flow rate (Qmax) improvement
were 19.4 mL, 1.68 ng/mL, 11.8/2.0 points, 32.9 mL, and
3.9 mL/s in group A and 11.5 mL, 1.98 ng/mL, 8.9/1.4
points, 53.8 mL, and 4.58 mL/s in group B. Poor clinical
outcome was observed in 24.3 % of patients from group A
and 47.4 % from group B (p = 0.04).
Conclusions PAE is a safe and effective technique that
can induce 48 % improvement in the IPSS score and a
prostate volume reduction of 19 %, with good clinical
outcome in up to 75 % of treated patients. Bilateral PAE
seems to lead to better clinical results; however, up to 50 %
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of patients after unilateral PAE may have a good clinical
outcome.
Keywords Prostatic arterial embolization  Unilateral 
Benign prostatic hyperplasia  Lower urinary tract
symptoms
Preliminary studies have shown that prostatic arterial
embolization (PAE) for the relief of lower urinary tract
symptoms (LUTS) in patients with prostate enlargement/
benign prostatic hyperplasia (PE/BPH) is a promising, new,
minimally invasive, image-guided therapy [1–4]. However,
PAE is a technically challenging procedure with unilateral
embolization and technical failure reported rates of
approximately 10–15 and 7 %, respectively [1–4]. To
perform the procedure in a safe manner without nontarget
embolization to periprostatic tissues, precise knowledge of
the male pelvic and PA anatomy and imaging findings is
required [5–7].
One of the reported series [2, 4] included one patient
with unilateral embolization (with almost 20 % reduction
in prostate volume and 11 % PSA reduction) and another
with bilateral PAE (with almost 50 % reduction in prostate
volume and 82 % PSA reduction). Both patients had sig-
nificant clinical relief. Another series [3] showed that
unilateral PAE might lead to moderate clinical relief with
8 % prostate volume reduction and 18 % reduction in PSA.
However, the preliminary case report described a patient
who underwent unilateral PAE with 38 % prostate volume
reduction, 90 % decrease in PSA, and significant clinical
relief [1].
We found no study to date that has compared the results
between unilateral versus bilateral PAE in the treatment of
LUTS in patients with PE/BPH. The purpose of this study
was to compare baseline data and clinical outcome between
patients who underwent unilateral and bilateral PAE for the
relief of LUTS.
Materials and methods
This single-center, ambispective, cohort study compared
122 consecutive patients who underwent unilateral versus
bilateral PAE from March 2009 to December 2011 (mean
patient age 66.7 ± 7.2 years) with PE/BPH who under-
went PAE for the relief of LUTS or for the treatment of
acute urinary retention (AUR). The institutional review
board approved the study, and a signed informed consent
was obtained from all patients.
All patients were evaluated by clinical observation
measuring the severity of LUTS with the international
prostate symptom score (IPSS) and the quality of life
(QoL) related to LUTS. Erectile function was evaluated
with the International Index of Erectile Function (IIEF).
Prostate volume (PV) assessment was performed by digital
rectal examination (DRE) and 2D-transrectal ultrasound
(TRUS) using the ellipsoid formula p/6 9 (transverse
diameter 9 anteroposterior diameter 9 sagittal diameter).
PSA was measured in all patients. Uroflowmetry measur-
ing the maximum flow rate (Qmax) and the postvoid
residual volume (PVR) was performed in all patients who
were not experiencing AUR. Pre-procedural sectional
imaging planning with CT angiography (CTA) to evaluate
the feasibility of PAE and study the pelvic arterial anatomy
was performed in all patients [5–7]. If the PSA level was
greater than 4 ng/mL or when the DRE or TRUS findings
were suspicious, prostatic biopsy was performed to exclude
malignancy.
Inclusion criteria for PAE included male patients, age
[40 years, prostate volume [30 cc, and diagnosis of PE/
BPH with moderate to severe LUTS refractory to medical
treatment for at least 6 months (IPSS[18 and/or QoL[3)
or under acute urinary retention refractory to medical
therapy. All patients were receiving medical therapy with
one alpha-1-adrenergic receptor antagonist (alfuzosin
10 mg, Ratiopharm, once daily; doxazosin 4 mg, Cardura
Gits, Pfizer, once daily; or tamsulosin 0.4 mg, Ratiopharm,
once daily). Thirty-one patients (25.4 %) also were medi-
cated with 5-alpha-reductase inhibitors (finasteride 5 mg,
Proscar, Merck Sharp & Dohme, once daily; or dutasteride
0.5 mg, Avodart, GlaxoSmithKline, once daily). Four
patients had previous prostatic surgery (TURP) years
before. Sixteen patients (13.1 %) were experiencing
AUR before PAE. Exclusion criteria included malignancy,
large bladder diverticula ([5 cm), large bladder stones
([2 cm), chronic renal failure (glomerular filtration rate
\60 mL/min; serum creatinine[1.2 mg/dl), tortuosity and
advanced atherosclerosis of iliac and/or prostatic arteries
(PAs) on pre-procedural CTA (on the basis of visual eval-
uation by the interventional radiologists), active urinary
tract infection, and unregulated coagulation parameters.
All patients were evaluated with IPSS/QoL, IIEF, PV,
PSA, Qmax, and PVR measurements. Baseline data were
assessed, and response to treatment was evaluated 1, 3, 6,
and 12 months after PAE.
Our procedure protocol has been described previously
[3]. We asked patients to stop all prostatic medication
1 week before embolization, if they were able to tolerate it.
If the procedure was clinically successful, patients were
told to abandon all prostatic medication after PAE. Two
days before PAE, in the day of PAE and on the following
10 days, patients were medicated with an acid-suppressing
drug (omeprazole 20 mg, Bluepharma, once daily), an anti-
inflammatory (naproxen 1,000 mg, Naprosyn, Roche,
twice daily), and an antibiotic (ciprofloxacin 750 mg, Jaba,
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twice daily). Patients were admitted to the hospital on the
morning of the procedure and were discharged the same
day if no complications occurred. During PAE analgesic
and anti-inflammatory drugs were given intravenously
(ketorolac 30 mg and metamizol 2 g).
A unilateral femoral approach (under local anesthesia)
was performed with a 5F 11-cm-long hydrophilic sheath
(Cordis, NJ, USA). A pigtail catheter (F5, Cordis) or the
Roberts uterine artery catheter (Cook, Bloomington, IN)
was introduced in the femoral artery with a 0.0350 hydro-
philic guidewire (Terumo, Tokyo, Japan) to perform the
crossover. Afterwards, the Waltman loop was reformed on
the Roberts uterine artery catheter that was used to cathe-
terize both hypogastric arteries. The catheter tip was left in
the proximal part of the anterior division of the hypogastric
arteries and digital subtraction angiography (DSA) using
nonionic optiray contrast medium (Ioversol, 350 mg I/ml;
Covidien, Dublin, Ireland; 6 mL, 3 mL/s, 3 frames/s) was
performed with ipsilateral anterior oblique projection (358)
and caudal-cranial angulation (108). Afterwards, the pros-
tatic vessels were selectively catheterized with a 2.4–2.7
F-microcatheter (Cantata, Cook; Progreat, Terumo, Tokyo,
Japan) and a 0.0160 guidewire (Sagitta, Cook; Glidewire
GT, Terumo). Selective prostatic artery DSA was per-
formed manually with 3-5 mL of contrast volume in neu-
tral and ipsilateral anterior oblique (358) and caudal-cranial
angulation (108) projection. Selective PAE was performed
with 100- and 200-lm nonspherical polyvinyl alcohol
(PVA) particles (Cook). The endpoint for embolization was
interruption of the arterial flow to the prostate, reflux, and
prostate gland opacification.
Procedure time (starting with femoral puncture access
and finished after removal of the catheter) and fluoroscopy
time were measured. Pain was measured using a visual
analogue scale (VAS; 0 = sensation of no pain;
10 = worst pain), by verbal questioning and written
questionnaires during and in the 6–8 h following PAE.
Postembolization symptoms and complications were
registered and classified according to the quality improve-
ment guidelines for percutaneous transcatheter emboliza-
tion [8]. All patients were evaluated by clinical and physical
examination with pain assessment in the day after PAE and
weekly in the following months.
Poor clinical outcome after PAE was considered when
one criterion was met: IPSS C20 and/or reduction \25 %;
QoL C4 and/or reduction \1; Qmax improvement
\2.5 mL/s; additional treatments required (need of pros-
tatic medication or surgery due to persisting severe LUTS)
[9, 10].
For comparisons of baseline and outcome variables
between the two groups, the paired t test and Fisher’s exact
tests were used. For comparisons of the change from
baseline of outcome variables between groups, an analysis
of covariance (ANCOVA) with adjustment for age was
used. For the comparison of poor clinical outcome, logistic
regression adjusted for age was used. Reported values are
means and standard deviations. Statistically significant
differences were assumed at p \ 0.05. Stata software
release 12 (Stata Corporation, College Station, TX) was
used for all statistical analyses.
Results
Bilateral PAE was performed in 103 (84.4 %) patients
(group A). The remaining 19 (15.6 %) patients underwent
unilateral PAE (group B). Mean follow-up time was
6.7 months in group A (1 year in 30 patients; 6 months in
43 patients; 3 months in 23 patients; and 1 month in 7
patients) and 7.3 months in group B (1 year in 10 patients;
6 months in 2 patients; 3 months in 7 patients). Most
patients who underwent unilateral PAE had significant
atherosclerotic lesions and tortuosity of the iliac and
prostatic arteries or prostatic arteries that arose from the
superior vesical artery with angled origins and tortuous
trajectory (Figs. 1, 2, 3).
Patients in group B were significantly older than patients
in group A (Table 1); however, no other statistically sig-
nificant differences were found in the baseline data
between groups. Overall, mean procedural time was
83.7 min (range 26–182) with a mean fluoroscopy time of
27.8 min (range 8–61). In group A, the mean procedural
time was 67.3 ± 30.9 min, and it was 96.3 ± 26.4 min in
group B (p = 0.0007). The mean fluoroscopy time was
18.1 ± 12.9 min in group A and 34.0 ± 10.3 min in group
B (p \ 0.0001).
Mean procedural pain score was 3.1 and 0.2 points after
PAE (before discharge), with 15 (12.2 %) patients dis-
charged the following day (inpatients) because of personal
preference (the remaining patients were treated as outpa-
tients and were discharged 6–8 h after PAE).
As minor complications, 12 (9.8 %) patients had urinary
tract infections after embolization treated with antibiotics
(10 patients from group A—9.7 % and 2 patients from
group B—10.5 %), transient hematuria in 16 (13.1 %)
patients, transient hemospermia in 8 (6.6 %) patients, and
transient rectal bleeding in 10 (8.2 %) patients that disap-
peared spontaneously without any treatment during the first
2 weeks. There were two cases of balanoprostatites (1.6 %)
and nine inguinal hematomas (7.4 %) that required no
additional treatment. Two patients had acute urinary
retention after PAE; for relief, a temporary bladder catheter
was placed at the time for a couple of hours and the
patients were able to void spontaneously before discharge.
No other minor or major complications were observed.
Sixteen patients were under AUR before PAE (13 from
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group A and 3 from group B) and all were able to remove
the bladder catheter and urinate spontaneously 15–60 days
after PAE.
Overall, there was a mean prostate volume reduction of
18.2 ± 22.1 mL (19.2 %, p \ 0.0001), a mean PSA
reduction of 1.73 ± 4.33 ng/mL (30.9 %, p \ 0.0001), a
mean IPSS/QoL improvement of 11.3 ± 8.74/1.93 ± 1.52
points (44.8 %/44.2 %, p \ 0.0001), a mean Qmax
improvement of 4.00 ± 4.75 mL/s (65 %, p \ 0.0001),
and a mean PVR reduction of 35.9 ± 93.2 mL (0.5 %,
p = 0.002). The IIEF improved 1.55 ± 6.44 points
(23.6 %, p = 0.017).
There was a statistically significant difference between
groups regarding clinical outcome with 47.4 % of patients
from group B and 24.3 % of patients from group A having
poor clinical outcome (23.1 % difference, p = 0.04). Age
was a confounder and after adjusting for age, this trend was
maintained but did not reach statistical significance. There
were no statistically significant differences in the
improvement rates of most evaluated parameters after PAE
between groups (Table 2). The PV volume reduced more
7.9 mL, the IPSS 2.9 points, and the QoL 0.6 points in
group A. The PSA, Qmax, and PVR improvements after
PAE did not differ significantly between groups.
There were 34 (27.9 %) patients with poor clinical
outcome after PAE (25 from group A—24.3 % and 9 from
group B—47.4 %). Six patients underwent subsequent
prostatic surgery (5 from group A—4.9 % and 1 from
group B—5.3 %), whereas 20 patients resumed prostatic
medication and remained under observation (13 from
Fig. 1 Unilateral prostatic arterial embolization (PAE). A Right
pelvic side, digital subtraction angiography (DSA) with ipsilateral
anterior oblique projection (358) and caudal-cranial angulation (108).
The prostatic artery (straight arrow) arises from the superior vesical
artery (curved arrow) with an angled origin (908). B Right pelvic side,
DSA with ipsilateral anterior oblique projection (358) and caudal-
cranial angulation (108). After various attempts to selective
catheterize the prostatic artery with a microcatheter, the artery was
dissected (curved arrow) and is no longer visible in the control
angiogram. C Left pelvic side, DSA with ipsilateral anterior oblique
projection (358) and caudal-cranial angulation (108) showing the left
prostatic artery (straight arrow). D Left prostatic artery DSA (straight
arrow) in neutral position showing anastomoses to the contralateral
prostatic artery (solid arrow)
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Fig. 2 Atherosclerotic lesions
that may lead to unilateral PAE.
A CTA, Sagittal MIP reformat
of the left pelvic side showing
an occlusion of the internal
pudendal artery (curved arrow)
above the prostatic artery origin
(straight arrow). B Left pelvic
side, DSA with ipsilateral
anterior oblique projection (358)
and caudal-cranial angulation
(108) showing the catheter tip
(solid arrow) near the occlusion
(curved arrow). There is left
prostatic artery (straight arrow)
retrograde opacification through
the vesical arteries (dotted
arrows). C Left pelvic side,
DSA with ipsilateral anterior
oblique projection (358) and
caudal-cranial angulation (108)
showing multiple
atherosclerotic stenoses of the
internal pudendal artery (curved
arrows) and a small and
tortuous prostatic artery
(straight arrow). D CTA, 3D
volume rendering reformat of
the right pelvic side showing
multiple atherosclerotic
stenoses of the internal
pudendal artery (curved arrows)
that may lead to technical
difficulties. E Right pelvic side,
DSA with ipsilateral anterior
oblique projection (358) and
caudal-cranial angulation (108).
Multiple atherosclerotic
stenoses (curved arrows) of the
internal iliac anterior division
and of the origin of the prostatic
artery (straight arrow) and
obturator artery (solid arrow)
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Fig. 3 Tortuosity and atherosclerosis of the right pelvic side arteries
(curved arrows) leading to unilateral PAE. A CTA, 3D MIP reformat.
B CTA, 3D volume rendering reformat. C Right pelvic side, DSA
with ipsilateral anterior oblique projection (358) and caudal-cranial
angulation (108). Note the catheter kinking due to tortuosity of the
right pelvic arteries (curved arrow). The prostatic artery (straight
arrow) has a tortuous trajectory, small diameter and arises from the
superior vesical artery with an angled origin (solid arrow)
Table 1 Baseline data between groups (group A, bilateral PAE; group B, unilateral PAE)
Baseline data Group A (n = 103) Group B (n = 19) P value
Mean age (mean ± SD, year) 65.8 ± 6.9 71.3 ± 1.7 0.002
PV (mean ± SD, mL) 84.1 ± 38.5 75.8 ± 30.8 0.38
PSA (mean ± SD, ng/mL) 5.6 ± 5.5 7.5 ± 9.3 0.22
IPSS (mean ± SD, points) 23.1 ± 6.8 21.9 ± 7.0 0.54
QoL (mean ± SD, points) 4.2 ± 0.9 3.9 ± 0.9 0.16
Qmax (mean ± SD, mL/s) 8.5 ± 4.2 8.4 ± 3.1 0.90
PVR (mean ± SD, mL) 93.9 ± 92.3 116.2 ± 86.9 0.37
5-ARI medication (%) 24.3 (n = 25) 31.6 (n = 6) 0.57
Diabetic (%) 15.5 (n = 16) 26.3 (n = 5) 0.32
AUR (%) 12.6 (n = 13) 15.8 (n = 3) 0.71
SD standard deviation; PV prostate volume; IPSS International Prostate Symptom Score; QoL quality of life; Qmax maximum flow rate; PVR
postvoid residual volume; 5-ARI 5-alpha-reductase inhibitors; AUR acute urinary retention
Table 2 Clinical response after PAE between groups (group A, bilateral PAE; group B, unilateral PAE)
D after PAE Group A (n = 103) Group B (n = 19) P value (unadjusted) P value (age-adjusted)
PV (mean ± SD, mL) -19.4 ± 22.7 (-20.5 %) -11.5 ± 17.7 (-11.9 %) 0.21 0.38
PSA (mean ± SD, ng/mL) -1.7 ± 4.4 (-30.4 %) -2.0 ± 4.1 (-26.7 %) 0.33 0.23
IPSS (mean ± SD, points) -11.8 ± 8.8 (-46.2 %) -8.9 ± 8.1 (-37.1 %) 0.29 0.55
QoL (mean ± SD, points) -2.0 ± 1.6 (-46.1 %) -1.4 ± 1.2 (-33.3 %) 0.34 0.66
Qmax (mean ± SD, mL/s) ?3.9 ± 4.4 (?63.9 %) ?4.6 ± 6.5 (?71.6 %) 0.66 0.59
PVR (mean ± SD, mL) -32.9 ± 93.8 (-5.6 %) -53.8 ± 90.6 (-25.9 %) 0.90 0.79
IIEF (mean ± SD, points) ?1.6 ± 6.6 (?24.5 %) ?1.1 ± 5.5 (?18.6 %) 0.41 0.93
Poor clinical outcome (%) 24.3 (n = 25) 47.4 (n = 9) 0.04 0.08
D variation; SD standard deviation; PV prostate volume; IPSS International Prostate Symptom Score; QoL quality of life; Qmax maximum flow
rate; PVR postvoid residual volume
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group A—12.6 % and 7 from group B—36.8 %). The
remaining eight patients (7 from group A—6.8 % and 1
from group B—5.3 %) had significant IPSS and QoL
improvements (requiring no additional medical or surgical
therapy) but were considered to have a poor outcome based
on the Qmax results (without improvement). Poor clinical
outcome after PAE based on symptomatic parameters and
on the need for further treatment was observed in 18
patients from group A (17.5 %) and 8 patients from group
B (42.1 %) (unadjusted p value of 0.03; age-adjusted
p value of 0.2). Overall, based on clinical symptomatic
parameters and on the need of further treatment, poor
outcome after PAE was observed in 26 (21.3 %) patients.
These differences were not statistically significant between
the two groups (Table 3).
Discussion
Pelvic arterial embolization to control severe bladder or
prostatic hemorrhage due to neoplasms after biopsy or
surgery has been reported in the past three decades with
hundreds of patients treated with success. It has proved to
be a safe and effective technique to control refractory, life-
threatening bladder, or prostate bleeding. The procedure
should be considered the treatment of choice, because it
obviates the need for emergency surgery in severely ill
patients [11–16]. Animal studies have reported that PAE is
a safe technique, inducing PV reduction, prostatic infarc-
tion, and ablation without sexual dysfunction [17–19].
The first report of PAE inducing LUTS relief was in a
patient with BPH (unfit for surgery) with severe prostatic
bleeding requiring multiple blood transfusions, refractory
to interstitial laser ablation, and external-beam radiation.
PAE stopped the hemorrhage and induced significative
LUTS relief, PV, and PSA reduction [1]. Based on these
reports, it has been suggested that PAE might follow
uterine artery embolization for fibroids [20].
The preliminary results in 16 patients with PE/BPH and
severe LUTS/experiencing acute urinary retention have
shown that PAE is safe and feasible procedure, with short-
and mid-term follow-up suggesting good symptom control
without sexual dysfunction, associated with a reduction in
PV and PSA. PAE is considered technically challenging
and unilateral PAE has been reported in all of these pre-
liminary studies [2–4]. In the present study, 15.6 % of
patients underwent unilateral embolization due to signifi-
cant atherosclerotic lesions and tortuosity of the iliac and
prostatic arteries.
All of the preliminary data results from single-center,
small-sized studies. To our knowledge, we found no studies
comparing unilateral and bilateral PAE in a large series of
patients. We aimed to analyze retrospectively the baseline
data between groups to see if there was any clinical pre-
dictor of unilateral PAE. We excluded patients with large
bladder diverticula, because these are patients at high risk
of poor outcome after embolization due to bladder dys-
function. Also, large bladder stones and large diverticula
should be removed surgically to avoid possible complica-
tions (hematuria, bladder cancer). Age was the only base-
line parameter that was statistically significantly different
between groups. Older patients were at greater risk of
unilateral PAE and were more likely to pose technical
difficulties (probably due to greater tortuosity and athero-
sclerotic changes of the pelvic arteries). Although there
was a greater rate of diabetic patients with unilateral
embolization, this trend did not reach statistical signifi-
cance. The mean procedural and fluoroscopy times were
significantly larger in patients with unilateral PAE reflect-
ing the technical difficulties (mean procedural times of
approximately 1 h for bilateral PAE and 1.5 h for unilateral
PAE; mean fluoroscopy times under 20 min for bilateral
PAE and approximately 30 min for unilateral PAE).
We prospectively compared clinical outcome between
patients with unilateral and bilateral embolization. As
expected, clinical outcome was better in patients with
bilateral PAE. However, approximately 50 % of patients
with unilateral embolization had a good clinical outcome,
whereas 75 % of patients with bilateral embolization
reported a good clinical outcome. As previously shown [6,
7], there may exist anastomoses between prostatic arteries
from both pelvic sides, which may partially explain these
results.
Table 3 Distribution of patients with poor clinical outcome stratified
according to each criterion (group A, bilateral PAE; group B, uni-
lateral PAE)






IPSS C20 and/or reduction
\25 % after PAE
13 (52 %) 6 (66.7 %)
QoL C4 and/or reduction
\1 after PAE
12 (48 %) 6 (66.7 %)
Qmax improvement
\2.5 mL/s after PAE
16 (64 %) 5 (55.6 %)
Need for prostatic medication
after PAE
13 (52 %) 7 (77.8 %)
Need for prostatic surgery
after PAE
5 (20 %) 1 (11.1 %)
No need for prostatic medication
or surgery after PAE
7 (28 %) 1 (11.1 %)
IPSS International Prostate Symptom Score; PAE prostatic arterial
embolization; QoL Quality of life; Qmax maximum flow rate
Data given in number of patients (percentages) of poor clinical out-
come stratified according to each criteria in each group (p [ 0.05,
Fisher’s exact test)
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Overall, all of the evaluated parameters improved sig-
nificantly after PAE. There was a mean IPSS improvement
of 11.3 points (44.8 %), and a mean QoL improvement of
1.93 points, with a prostate volume reduction of 19.2 %
and a PSA reduction of 30.9 %. Almost all of these
changes were better after bilateral PAE; however, the dif-
ferences between groups did not reach statistical signifi-
cance. There was a greater IPSS/QoL improvement and PV
reduction after bilateral PAE; however, the PSA reduction,
the Qmax improvement, and the PVR reduction were
slightly better after unilateral PAE (non significant differ-
ences). We believe that this is due to the fact that LUTS in
PE/BPH patients is very complex and may be caused by
many factors. Also, there is a short follow-up time. How-
ever, the great variability of the results in both groups
(unilateral and bilateral PAE) may be one of the main
reasons why these differences did not reach statistical
significance. Unilateral PAE may be one of many con-
founding factors that undermine the clinical outcome after
PAE for PE/BPH.
The relief of the bladder obstruction did not follow the
magnitude of clinical improvement (mean Qmax improve-
ment of 4.0 mL/s; mean PVR reduction of 35.9 mL). This is
not surprising, because PAE does not remove prostatic tis-
sue. The IIEF had a slight improvement (1.55 points)
probably due to the discontinuation of all prostatic medi-
cation after PAE.
We were able to perform PAE as an outpatient proce-
dure in almost 90 % of patients with minimal pain asso-
ciated and no vomiting or other postembolization
symptoms. No major complications were reported in this
study, and all minor complications could be addressed with
medical/conservative care. Approximately 30–40 % of
patients experience a burning sensation in the urethra and
irritative voiding (frequency, urgency) in the first 2 weeks
after PAE. These symptoms may range from light to very
severe and may raise the suspicion of a urinary tract
infection (we only considered those cases with positive
urine cultures). Patients should be warned that this is a
normal finding after PAE and that is usually self-limited,
disappearing after the first 2 weeks. We did not consider
these symptoms as minor complications. We had approx-
imately 10 % of urinary tract infections despite the anti-
biotic coverage before and after PAE (with no differences
between groups).
Up to 27.9 % of patients had poor clinical outcome after
PAE. If the Qmax criteria were neglected and only
symptomatic parameters were evaluated (IPSS/QoL and
the need of further prostatic treatment), poor outcome after
PAE was observed in 21.3 % patients. After unilateral
PAE, 11 % of patients (n = 1) had significant IPSS/QoL
improvements and required no additional treatments but
were considered to have poor outcome due to the Qmax
criteria. The same applied to 28 % of patients (n = 7) after
bilateral PAE, with no significant differences between
groups. Once more, the dissociation between clinical and
urodynamic improvements partially explains these results.
Most of the patients with poor clinical outcome remained
under observation and resumed the prostatic medication
with only six (4.9 %) patients needing to undergo surgery.
The patients with good clinical outcome remained without
any prostatic medication.
This study has limitations. The follow-up time is not
very long (and different between groups), and we did not
compare PAE with other therapeutical options or placebo.
There were no pressure-flow urodynamics performed
(which may help to exclude patients with LUTS due to
other causes such as bladder dysfunction), and the study
was not randomized. The endpoint follow-up period in
each group and between groups was not the same for all
patients.
PAE is a safe and effective technique that can induce
45 % improvement in the IPSS score and a prostate volume
reduction of 19 %, with good clinical outcome in up to 75
% of treated patients. Bilateral PAE seems to lead to better
clinical results; however, up to 50 % of patients after
unilateral PAE may have a good clinical outcome.
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